NLRP3 and Alzheimer disease: Previous studies have shown that NLRP3 inflammasome activation is prevalent in AD mouse models and in human postmortem brains [7, 16, 46, 47] and suggest that inhibition of this sensor protein may be a therapeutic target for AD.